Carlsquare recently initiated coverage of Dancann Pharma with a fair value per share of DKK 6.5. Read the full report here.
On March 2 2021, DanCann Pharma A/S (DanCann or the company) signed a letter of intent with Tetra Bio-Pharma for the distribution of three cannabis based medical products. Today, DanCann released the information that the letter of intent has been converted to a formal agreement. DanCann receives distribution rights in the Nordic countries and Germany for Reduvo Adversa® and Qixleef™.
LÄS MER